Drugs / Pentabio
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT05482282 Comparator | Dec 2025 → Dec 2026 | hepatitis B virus infection | PT Bio Farma | Withdrawn | No outcome recorded |
| Phase 3 | NCT04071379 Comparator | Oct 2020 → Apr 2021 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 4 | NCT03310073 Background | Jul 2016 → Mar 2017 | — | PT Bio Farma | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-13 | PT Bio Farma | Bio Farma Daftarkan Pentabio ke WHO co.id ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentabio | “Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B” NCT04071379 ↗ |
| Known as | Pentabio Vaccine | “Pentabio® Vaccine” NCT05482282 ↗ |
| Modality | Vaccine | “Pentabio® Vaccine” NCT04071379 ↗ |